礼来加码抗癌新赛道：12.5亿美元携手Magnet Bio开发分子胶药物_老虎社区_美港股上老虎

礼来加码抗癌新赛道：12.5亿美元携手Magnet Bio开发分子胶药物

智通财经03-01

3月1日，生物技术公司Magnet Biomedicine周五宣布，已与礼来达成一项价值高达12.5亿美元的许可协议，双方将利用Magnet的TrueGlue发现平台共同开发癌症药物。根据协议，Magnet将从礼来获得高达4000万美元的预付款和近期付款以及股权，作为双方启动研究的资金支持。双方将利用Magnet的TrueGlue平台开发用于癌症治疗的分子胶疗法。此外，Magnet还有资格根据开发...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2514532436?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2025-03-01 01:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514532436","market":"us","top_or_hot":-1,"title":"礼来加码抗癌新赛道：12.5亿美元携手Magnet Bio开发分子胶药物","media":"智通财经","content":"<div>\n<p>3月1日，生物技术公司Magnet Biomedicine周五宣布，已与礼来达成一项价值高达12.5亿美元的许可协议，双方将利用Magnet的TrueGlue发现平台共同开发癌症药物。根据协议，Magnet将从礼来获得高达4000万美元的预付款和近期付款以及股权，作为双方启动研究的资金支持。双方将利用Magnet的TrueGlue平台开发用于癌症治疗的分子胶疗法。此外，Magnet还有资格根据开发...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1256470.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼来加码抗癌新赛道：12.5亿美元携手Magnet Bio开发分子胶药物</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼来加码抗癌新赛道：12.5亿美元携手Magnet Bio开发分子胶药物\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-01 01:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1256470.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月1日，生物技术公司Magnet Biomedicine周五宣布，已与礼来达成一项价值高达12.5亿美元的许可协议，双方将利用Magnet的TrueGlue发现平台共同开发癌症药物。根据协议，Magnet将从礼来获得高达4000万美元的预付款和近期付款以及股权，作为双方启动研究的资金支持。双方将利用Magnet的TrueGlue平台开发用于癌症治疗的分子胶疗法。此外，Magnet还有资格根据开发...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1256470.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SGXZ57979304.SGD","symbol_name":"United Global Healthcare A Acc SGD-H","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1256470.html","article_id":"2514532436","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514532436","pubTimestamp":1740763888,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，生物技术公司Magnet Biomedicine周五宣布，已与礼来达成一项价值高达12.5亿美元的许可协议，双方将利用Magnet的TrueGlue发现平台共同开发癌症药物。根据协议，Magnet将从礼来获得高达4000万美元的预付款和近期付款以及股权，作为双方启动研究的资金支持。据了解，Magnet的TrueGlue平台旨在开发能够促进蛋白质间相互作用并在患者中产生具有临床意义的治疗反应的小分子。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0058720904.USD":"联博国际健康护理基金A","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","SGXZ81514606.USD":"大华环球创新基金A Acc USD","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","BK4581":"高盛持仓","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0238689110.USD":"贝莱德环球动力股票基金","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LLY":"礼来","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","BK4534":"瑞士信贷持仓","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0079474960.USD":"联博美国增长基金A","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0122379950.USD":"贝莱德世界健康科学A2"},"translate_title":"Eli Lilly increases its investment in new anti-cancer track: US $1.25 billion joins hands with Magnet Bio to develop molecular glue drugs","themeId":"","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/2fe374a94db88bf1484bb70b4993a9c0","symbols_score_info":{"LLY":1},"content_text":"3月1日，生物技术公司Magnet Biomedicine周五宣布，已与礼来达成一项价值高达12.5亿美元的许可协议，双方将利用Magnet的TrueGlue发现平台共同开发癌症药物。根据协议，Magnet将从礼来获得高达4000万美元的预付款和近期付款以及股权，作为双方启动研究的资金支持。双方将利用Magnet的TrueGlue平台开发用于癌症治疗的分子胶疗法。此外，Magnet还有资格根据开发、监管和商业里程碑的实现情况，获得全球净销售额的分级特许权使用费以及超过12.5亿美元的里程碑付款。据了解，Magnet的TrueGlue平台旨在开发能够促进蛋白质间相互作用并在患者中产生具有临床意义的治疗反应的小分子。Magnet首席执行官Brian Safina表示：“礼来致力于创新，并在为患者带来变革性药物方面拥有深厚的专业知识，这使其成为Magnet的理想合作伙伴，我们将共同挖掘分子胶的未开发潜力。”","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}